Loading…
← CockpitCompetitor Analysis › 039200.KS Oscotec Inc.Open in the cockpit ↗

Oscotec Inc.039200.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean biotech developing kinase-inhibitor cancer drugs, with a subsidiary that licensed a leukemia drug candidate to a global partner.

Momentum neutral 54
Mkt cap
$923M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$3.29M
20-day average traded
Fwd P/E
50.2×
forward earnings
ROIC−WACC
+147.7 pp
WACC 5.6%
Hurdle
-28 pp
Req g minus delivered
Next earnings
126 days
24 Mar 2027
Close · KRW₩32,300
1D-1.4%
1W-13.9%
1M-13.9%
3M-13.6%
6M-32.3%
YTD-28.5%
1Y-32.9%
ATR %6.8%
52w lowhigh51.1% off high

What Oscotec does

Korean biotech developing kinase-inhibitor cancer drugs, with a subsidiary that licensed a leukemia drug candidate to a global partner.

Has no marketed product of its own, so it relies on milestone payments from licensing partners and on share sales while candidates move through trials. Kinase inhibitors, the drug class it works in, block enzymes that tumours depend on.

Products and services

  • Kinase-inhibitor drug pipeline
  • Licensed leukemia drug candidate

Customers

  • Global pharma licensing partners

Where it sits in the supply chain

  • Biotechnology
  • Kinase-inhibitor oncology drugs
  • Global pharma licensing

What could go right

  • Licensing milestone payments
  • Clinical progress on partnered assets

What could go wrong

  • Clinical-trial failure risk
  • Early-stage pipeline concentration

Moat: narrow (IP / patents). Kinase-inhibitor drug-discovery platform validated by an out-licensed leukemia candidate.

Headquarters: Seongnam, South Korea · Founded: 1998 · Employees: 57

Named competitors

Oscotec at a glance

Size Oscotec (039200.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $923M, the 246th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩32,300 on 18 Nov 2026.

Performance Over six months the shares fell 32.3%, against -16.9% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 510.3% over the last twelve months (peer median +2.4%); the operating margin is 58.8% (peer median 7.1%).

Valuation It trades at 50.2× forward earnings against a peer median of 22.2× (most expensive of 9).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -28 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 147.7 points above its cost of capital (5.6% WACC).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 84039200.KS 68
Six months, rebased to 100: Oscotec against the median of its 20 peers (local-currency closes).

Oscotec financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩142B₩99.8B₩34.0B₩4.95B₩5.06B
Revenue growth—+194%+587%-2%—
Gross profit₩139B₩96.5B₩30.2B₩1.23B₩1.57B
EBITDA₩84.9B₩53.7B-₩795M-₩30.8B-₩26.9B
Net income₩76.9B₩52.6B₩877M-₩24.3B-₩24.4B
Free cash flow₩86.5B₩7.52B-₩26.7B-₩22.6B-₩27.7B
Capital expenditure₩1.48B₩780M₩692M₩581M₩1.25B
Total debt₩17.1B₩15.6B₩13.8B₩24.6B₩10.1B

Quarterly statements and history in the cockpit →

Oscotec competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-25%0%+25%3004011795MLTX688177IMTX25956002526004220024376885536035382005AKTS6887594565PGHL039200.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Oscotec is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%20×40×3004011795603538STAR20053002944565PGHL039200.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Oscotec is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%3004011795600252002437688553603538STAR20050005974565PGHL039200.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Oscotec is the large dot.

Oscotec competitors and peer comparison

Head to head with its named competitors (039200.KS vs 310210.KS vs 128940.KS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Oscotec 039200.KS$923M-32%+510%59%50.2×-10.2%
Voronoi 310210.KS$1.43B-62%-100%-438,152%n/an/a
HanmiPharm 128940.KS$3.95B-2%+14%16%15.0×4.7%

How Oscotec compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Oscotec against its 20 peers (data as of 18 Nov 2026)
Measure039200.KSPeer medianRank in peer set
1-month return-13.9%-9.1%7th lowest of 21
6-month return-32.3%-16.9%7th lowest of 20
Distance from 52-week high-51.1%-46.6%7th lowest of 21
Revenue growth (TTM)+510.3%+2.4%highest of 18
Operating margin58.8%7.1%highest of 18
Forward P/E50.2×22.2×most expensive of 9
Growth the price implies (Req g, 7 yrs)-10.2%9.1%least demanding of 12
Growth delivered (Del g)+18.1%+4.9%2nd highest of 12
Hurdle (Req g minus delivered)-28.3 pp+2.8 ppleast demanding of 12
ROIC minus cost of capital+147.7 pp-2.0 pphighest of 15
EV / EBITDA12.5×11.1×3rd most expensive of 6
Net debt / EBITDA-2.0×2.1×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Oscotec 039200.KSSouth Korea$923M-32%+510%59%50.2×-10.2%+18.1%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%22.9×9.1%+13.4%
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%9.8×-3.7%+13.8%
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%n/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%n/an/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%n/a10.3%-13.7%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%

Questions

Who are Oscotec's main competitors?
Named competitors: Voronoi (310210.KS), HanmiPharm (128940.KS). The cockpit's measured peer set (industry) also includes Zhejiang Garden Biopharmaceutical (300401.SZ), Lotus Pharmaceutical (1795.TW), MoonLake Immunotherapeutics (MLTX), Bio-Thera Solutions (688177.SS), Immatics (IMTX), Genfleet Therapeutics (Shanghai) (2595.HK).
Is Oscotec expensive compared with its peers?
On forward p/e it trades at 50.2× against a peer median of 22.2×, most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -28 pp: the price already allows for a slowdown.
How has Oscotec stock performed?
Over six months to 18 Nov 2026 the shares returned -32.3% against -16.9% for the median peer; over one year -32.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.